Daré Bioscience Reported FY23 Revenue of $2.8M Vs $2.07M Est, EPS Loss of $(0.35) Vs $(0.38) Est, Cash Balance of $10.5M
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience reported its FY23 financial results, with a revenue of $2.8M surpassing the $2.07M estimate. The EPS loss was $(0.35), better than the $(0.38) estimate. The company also reported a cash balance of $10.5M.
March 28, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daré Bioscience reported higher than expected FY23 revenue and a smaller EPS loss than anticipated, with a solid cash balance.
The positive earnings report, surpassing both revenue and EPS estimates, indicates a strong financial performance by Daré Bioscience. This is likely to instill investor confidence and could lead to a short-term uptick in the stock price. The reported cash balance further supports the company's financial stability.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100